We use cookies to understand how visitors search for and consume the information we provide, so that we can improve their experience. By browsing this website, you indicate your acceptance of the use of such cookiesAcceptRead more

Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Our products& pipeline
    • Diseases we target
    • GS010 for LHON
    • GS030 for Retinitis Pigmentosa
    • GS030 for Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
  • Investors& media
    • Company Overview
    • Press releases
    • Events & presentations
    • Stock information
    • Governance
    • Documentation

Our technologies

To bring the most advanced scientific thinking to finding a treatment for inherited neurodegenerative diseases, we combine gene therapy with platforms such as mitochondrial targeting sequence and optogenetics.
Direct access
  • Technologies we are applying
  • Gene Therapy
  • Mitochondrial Targeting Sequence (MTS)
  • Optogenetics
  • Home >
  • Our technologies
  • Technologies we are applying
  • Gene Therapy
  • Mitochondrial Targeting Sequence (MTS)
  • Optogenetics

Stay informed

Subscribe to the newsletter to get the latest GenSight Biologics news

Fields marked with an * are required
© 2019 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
Go back to the page of the page